AngioDynamics 2Q Loss Narrows, Revises FY25 Outlook

Dow Jones

Jan 08, 2025

By Denny Jacob

AngioDynamics narrowed its loss in its latest quarter even as sales declined from a year earlier.

The medical-device maker narrowed its loss to $10.7 million, or 26 cents a share, for the second quarter ended Nov. 30, from about $29 million, or 72 cents a share, a year earlier.

Stripping out one-time items, the loss came in at 4 cents a share. Analysts polled by FactSet expected a loss of 11 cents a share.

Sales declined to $72.8 million from $79.1 million, above analysts' estimates of $70.9 million. On a pro-forma basis, sales rose 9.2% to about $73 million.

Medical-technology pro-forma net sales rose 25% to $31.5 million, while medical-device pro-forma net sales ticked down 0.4% to $41.5 million.

For fiscal 2025, AngioDynamics now sees an adjusted loss per share in the range of 34 cents to 38 cents compared with its prior guidance set between 38 cents and 42 cents.

Chief Executive Jim Clemmer said the company now expects adjusted earnings before interest, taxes, depreciation, and amortization to be positive for the fiscal year.

Write to Denny Jacob at denny.jacob@wsj.com

(END) Dow Jones Newswires

January 08, 2025 07:05 ET (12:05 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2501255027"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2501255027\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2501255027?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-08 20:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2501255027","market":"sh","top_or_hot":-1,"title":"AngioDynamics 2Q Loss Narrows, Revises FY25 Outlook","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Denny Jacob \n</p>\n<pre>\n \n</pre>\n<p>\n  AngioDynamics narrowed its loss in its latest quarter even as sales declined from a year earlier. \n</p>\n<p>\n  The medical-device maker narrowed its loss to $10.7 million, or 26 cents a share, for the second quarter ended Nov. 30, from about $29 million, or 72 cents a share, a year earlier. \n</p>\n<p>\n  Stripping out one-time items, the loss came in at 4 cents a share. Analysts polled by FactSet expected a loss of 11 cents a share. \n</p>\n<p>\n  Sales declined to $72.8 million from $79.1 million, above analysts' estimates of $70.9 million. On a pro-forma basis, sales rose 9.2% to about $73 million. \n</p>\n<p>\n  Medical-technology pro-forma net sales rose 25% to $31.5 million, while medical-device pro-forma net sales ticked down 0.4% to $41.5 million. \n</p>\n<p>\n  For fiscal 2025, AngioDynamics now sees an adjusted loss per share in the range of 34 cents to 38 cents compared with its prior guidance set between 38 cents and 42 cents. \n</p>\n<p>\n  Chief Executive Jim Clemmer said the company now expects adjusted earnings before interest, taxes, depreciation, and amortization to be positive for the fiscal year. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Denny Jacob at denny.jacob@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 08, 2025 07:05 ET (12:05 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AngioDynamics 2Q Loss Narrows, Revises FY25 Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAngioDynamics 2Q Loss Narrows, Revises FY25 Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-01-08 20:05</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Denny Jacob \n</p>\n<pre>\n \n</pre>\n<p>\n  AngioDynamics narrowed its loss in its latest quarter even as sales declined from a year earlier. \n</p>\n<p>\n  The medical-device maker narrowed its loss to $10.7 million, or 26 cents a share, for the second quarter ended Nov. 30, from about $29 million, or 72 cents a share, a year earlier. \n</p>\n<p>\n  Stripping out one-time items, the loss came in at 4 cents a share. Analysts polled by FactSet expected a loss of 11 cents a share. \n</p>\n<p>\n  Sales declined to $72.8 million from $79.1 million, above analysts' estimates of $70.9 million. On a pro-forma basis, sales rose 9.2% to about $73 million. \n</p>\n<p>\n  Medical-technology pro-forma net sales rose 25% to $31.5 million, while medical-device pro-forma net sales ticked down 0.4% to $41.5 million. \n</p>\n<p>\n  For fiscal 2025, AngioDynamics now sees an adjusted loss per share in the range of 34 cents to 38 cents compared with its prior guidance set between 38 cents and 42 cents. \n</p>\n<p>\n  Chief Executive Jim Clemmer said the company now expects adjusted earnings before interest, taxes, depreciation, and amortization to be positive for the fiscal year. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Denny Jacob at denny.jacob@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 08, 2025 07:05 ET (12:05 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2501255027","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2501255027","pubTimestamp":1736337900,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"AngioDynamics narrowed its loss in its latest quarter even as sales declined from a year earlier.The medical-device maker narrowed its loss to $10.7 million, or 26 cents a share, for the second quarter ended Nov. 30, from about $29 million, or 72 cents a share, a year earlier.Stripping out one-time items, the loss came in at 4 cents a share. Analysts polled by FactSet expected a loss of 11 cents a share.Sales declined to $72.8 million from $79.1 million, above analysts' estimates of $70.9 million. On a pro-forma basis, sales rose 9.2% to about $73 million.Medical-technology pro-forma net sales rose 25% to $31.5 million, while medical-device pro-forma net sales ticked down 0.4% to $41.5 million.For fiscal 2025, AngioDynamics now sees an adjusted loss per share in the range of 34 cents to 38 cents compared with its prior guidance set between 38 cents and 42 cents.Chief Executive Jim Clemmer said the company now expects adjusted earnings before interest, taxes, depreciation, and amortizat","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","ANGO":"Angiodynamics"},"translate_title":"AngioDynamics第二季度亏损收窄，修正2025财年展望","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ANGO":1},"content_text":"By Denny Jacob \n\n\n \n\n\n  AngioDynamics narrowed its loss in its latest quarter even as sales declined from a year earlier. \n\n\n  The medical-device maker narrowed its loss to $10.7 million, or 26 cents a share, for the second quarter ended Nov. 30, from about $29 million, or 72 cents a share, a year earlier. \n\n\n  Stripping out one-time items, the loss came in at 4 cents a share. Analysts polled by FactSet expected a loss of 11 cents a share. \n\n\n  Sales declined to $72.8 million from $79.1 million, above analysts' estimates of $70.9 million. On a pro-forma basis, sales rose 9.2% to about $73 million. \n\n\n  Medical-technology pro-forma net sales rose 25% to $31.5 million, while medical-device pro-forma net sales ticked down 0.4% to $41.5 million. \n\n\n  For fiscal 2025, AngioDynamics now sees an adjusted loss per share in the range of 34 cents to 38 cents compared with its prior guidance set between 38 cents and 42 cents. \n\n\n  Chief Executive Jim Clemmer said the company now expects adjusted earnings before interest, taxes, depreciation, and amortization to be positive for the fiscal year. \n\n\n \n\n\n  Write to Denny Jacob at denny.jacob@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 08, 2025 07:05 ET (12:05 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}